Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024
March 25, 2024 at 03:00 am
Share
Santen Pharmaceutical Co., Ltd. announced the change of Representative Director of the Board. This change was made as the Board received offer from Akira Kurokawa, Representative Director of the Board, Chairman, to resign from his position as Representative Director of the Board, effective from April 1, 2024. Takeshi Ito (Representative Director of the Board, President and Chief Executive Officer) is the only Representative Director of the Board of the Company after this change.
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024